Cboe Global earnings beat by $0.21, revenue topped estimates
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
What's breaking now, across thousands of outlets.
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
In plain terms: Private equity firms haven’t been building new capacity – they’ve been buying up the capacity that already existed.
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.